Table 1.

Baseline demographics of adult cystic fibrosis patients with known S. pyogenes Sputum isolates

Patient	Agea	Sex	Mutation 1	Mutation 2	Pancreatic Status	Current Smoker	Baseline FEV1 (L)b (% predicted)	Baseline FVC (L)c (% predicted)	TISd	AZMe	LABAf	ICSg	CFh Co-morbidities
1	19	M	F508del	F508del	I	N	2.62 (74)	4.09(100)	Y	N	N	N	DIOS, B
2	19	M	F508del	3849+1G->A	I	N	3.07 (71)	-	N	N	N	N	Liver, S
3	34	M	F508del	E56K	S	N	3.87 (106)	4.98(115)	N	N	N	N	None
4	18	F	M1101K	M1101K	I	N	2.22 (71)	3.06(93)	Y	N	N	N
5	24	F	F508del	F508del	I	Unknown	1.19 (35)	1.84(47)	N	N	N	N	DIOS
6	28	F	F508del	F508del	I	N	2.39 (89)	3.72(122)	N	N	N	N	IGT,DIOS
7	38	F	F508del	R347H	S	Unknown	2.15 (77)	3.14(95)	N	N	N	N	S
8	48	M	F508del	F508del	I	N	2.30 (54)	4.79(90)	Y	Y	Y	N	IGT
9	19	M	1717-1G->A	Unknown	S	N	3.73 (82)	4.55(85)	N	N	N	N	S
10	21	M	F508del	F508del	I	Y	2.63 (40)	3.61(84)	N	N	N	N	DIOS
11	33	F	F508del	R334W	I	N	1.11 (71)	2.34(74)	N	N	N	N	DIOS
12	26	M	G542x	Unknown	I	Y	2.96 (69)	4.99(100)	N	Y	Y	N	CFRD
13	26	F	Unknown	Unknown	I	N	2.80 (88)	4.10(108)	Y	N	N	N	CFRD,B, S, DIOS,
14	24	M	F508del	F508del	I	N	3.84 (84)	5.80(115)	Y	N	N	Y	Liver
15	28	F	M1101K	M1101K	I	N	2.67 (91)	3.37 (101)	N	N	N	N	B,S

I insufficient, S sufficient, Y yes, N no

^a Age at time of first S. pyogenes isolation.

^b Baseline FEV ₁ forced expiratory volume in one second recorded 2 years prior to the index GAS isolate

^c Baseline FVC forced volume capacity recorded 2 years prior to the index GAS isolate

^d TIS Chronic inhaled tobramycin therapy

^e AZM Chronic azithromycin

^f LABA Long-acting beta agonist

^g ICS Inhaled corticosteroid

^h CF Comorbidities, DIOS Distal Ileal Obstruction Syndrome, B osteoporosis, Liver liver disease, S sinus disease, IGT Impaired Glucose Tolerance, CFRD CF related diabetes